Loading...
•
Sep 30, 2023
Aura Biosciences Q3 2023 Earnings Report
Aura Biosciences reported third quarter 2023 financial results and provided clinical development and operational highlights.
Key Takeaways
Aura Biosciences reported progress across its portfolio, highlighted by the FDA agreement under the SPA for the CoMpass Phase 3 clinical trial and positive clinical efficacy updates of Bel-sar for early-stage choroidal melanoma. The company raised gross proceeds of $99.0 million in an underwritten public offering, strengthening its financial position to execute its pipeline.
Received FDA agreement under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical Trial.
Presented positive clinical efficacy updates of Bel-sar for early-stage Choroidal Melanoma from the ongoing Phase 2 Clinical Trial at AAO 2023.
Reported preliminary data from Phase 1 trial in Bladder Cancer with a clinical complete response in the first patient utilizing a single dose of Bel-sar with light activation.
Raised gross proceeds of $99.0 Million in an underwritten public offering.
Forward Guidance
Aura Biosciences believes its current cash and cash equivalents, marketable securities, and proceeds from the underwritten public offering are sufficient to fund its operations into the second half of 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...